西格列汀联合恩格列净治疗难治性糖尿病对患者血糖水平及炎症反应的影响  

Effect of Sitagliptin Combined with Empagliflozin on Blood Glucose Level and Inflammatory Response in Patients with Refractory Diabetes Mellitus

作　　者：李文辉 杨金河 谢远胜 LI Wenhui;YANG Jinhe;XIE Yuansheng(Department of General Practice,Qingliu Maternal and Child Health Hospital,Sanming,Fujian Province,365300 China;Department of Infection,Sanming First Hospital,Sanming,Fujian Province,365000 China)

机构地区：[1]清流县妇幼保健院全科医学科,福建三明365300 [2]三明市第一医院感染科,福建三明365000

出　　处：《糖尿病新世界》2023年第6期95-98,118,共5页Diabetes New World Magazine

摘　　要：目的探究西格列汀联合恩格列净治疗难治性糖尿病对患者血糖水平及炎症反应的影响。方法选取2019年6月—2020年9月清流县妇幼保健院收治的120例难治性糖尿病患者,以随机数表方法分组,每组60例。两组患者均采用地特胰岛素常规治疗,在此基础上,给予对照组口服磷酸西格列汀片,研究组同时服用磷酸西格列汀片和恩格列净片。对比两组患者治疗效果、血糖水平和炎症因子水平。结果研究组总有效率86.67%高于对照组71.67%,差异有统计学意义(P<0.05)。治疗后,研究组血糖(FPG、2 hPG、HbA1c)水平、炎症因子(IL-6、IL-8、TNF-α)水平低于对照组,差异有统计学意义(P<0.05)。治疗后,研究组β细胞功能指数(HOMA-β)、胰岛素抵抗指数(HOMA-IR)均优于对照组,差异有统计学意义(P<0.05)。结论西格列汀联合恩格列净治疗难治性糖尿病疗效显著,可以降低患者血糖、炎症因子水平,缓解炎症,有利于病情控制。Objective To explore the effects of sitagliptin combined with Empagliflozin on blood glucose level and inflammatory response in patients with refractory diabetes.Methods 120 patients with refractory diabetes admitted to Qingliu County Maternal and Child Health Hospital from June 2019 to September 2020 were selected,they were divided into groups using a random number table method,with 60 cases in each group.Both groups of patients were treated with regular insulin therapy,and on this basis,the control group was given oral Siagliptin Phosphate tablets,while the study group was given both Siagliptin Phosphate tablets and Engliflozin tablets.Compared the treatment efficacy,blood glucose levels,and inflammatory factor levels between two groups of patients.Results The total effective rate of the study group was 86.67%,higher than that of the control group 71.67%,and the difference was statistically significant(P<0.05).After treatment,the levels of blood glucose(FPG,2 hPG,HbA1c)and inflammatory factors(IL6,IL-8,TNF-α)in the study group were lower than those in the control group,and the difference was statistically significant(P<0.05).After treatment,the homeostasis model assessment-β(HOMA-β)and homeostasis model assessment-IR(HOMA-IR)of the study group were better than those of the control group,and the difference was statistically significant(P<0.05).Conclusion Sitagliptin combined with Empagliflozin is effective in the treatment of refractory diabetes,which can reduce the levels of blood glucose and inflammatory factors,relieve inflammation,and help to control the disease.

关 键 词：2型糖尿病 西格列汀 恩格列净 炎症因子 

分 类 号：R587[医药卫生—内分泌]